决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Genomic analysis reveals molecular characterization of CD30(+) and CD30(-) extranodal natural killer/T-cell lymphomas (ENKTLs).
CD30在55.74%的ENKTL中呈阳性。
结外自然杀伤(NK)/T细胞淋巴瘤(ENKTL)在亚洲人群中高发;然而,对其分子特征的了解甚少。在本研究中,我们检测了ENKTL中CD30的表达,随后对10对CD30+ENKTL和CD30-ENKTL配对样本进行了全外显子组测序。CD30在55.74%的ENKTL中呈阳性。单核苷酸和插入/缺失多态性分析显示,CD30+ENKTL中53.41%的体细胞突变与CD30-ENKTL共享,包括SERPINA9、MEGF6、MUC6和KDM5A的突变。频繁突变的基因主要与细胞增殖和迁移、肿瘤微环境、能量与代谢、表观遗传调控因子、血管重塑和神经功能相关。PI3K-AKT、cAMP、cGMP-PKG和AMPK通路在CD30+和CD30-ENKTL中均富集。拷贝数变异分析在CD30+ENKTL中鉴定出一组独特的基因,包括T细胞受体基因(TRBV6-1和TRBV8)、细胞周期相关基因(MYC和CCND3)、免疫相关基因(GPS2、IFNA14、TTC38和CTSV),以及大量泛素化相关基因(USP32、TRIM23、TRIM2、DUSP7和UBE2QL1)。在6/10的CD30+ENKTL和7/10的CD30-ENKTL中鉴定出BCL10突变。免疫组化分析显示,BCL10在正常淋巴组织中的表达模式与BCL2相似;然而,其在ENKTL细胞中的表达显著更高(67.92% vs. 16.98%),提示BCL10抑制剂在治疗ENKTL方面具有潜在应用价值。这些结果为CD30+和CD30-ENKTL的遗传特征提供了新的见解,并可能促进ENKTL新型疗法的临床开发。
Extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is prevalent in the Asian population; however, little is known about its molecular characteristics. In this study, we examined the CD30 expression in ENKTLs and then performed whole exome sequencing on ten CD30 + ENKTL and CD30 - ENKTL paired samples. CD30 was positive in 55.74% of the ENKTLs. Single nucleotide and insertion/deletion polymorphism analyses revealed that 53.41% of the somatic mutations in CD30 + ENKTLs were shared with CD30 - ENKTLs, including mutations in SERPINA9, MEGF6, MUC6, and KDM5A. Frequently mutated genes were primarily associated with cell proliferation and migration, the tumor microenvironment, energy and metabolism, epigenetic modulators, vascular remodeling, and neurological function. PI3K-AKT, cAMP, cGMP-PKG, and AMPK pathways were enriched in both CD30 + and CD30 - ENKTLs. Copy number variation analysis identified a unique set of genes in CD30 + ENKTLs, including T-cell receptor genes (TRBV6-1 and TRBV8), cell cycle-related genes (MYC and CCND3), immune-related genes (GPS2, IFNA14, TTC38, and CTSV), and a large number of ubiquitination-related genes (USP32, TRIM23, TRIM2, DUSP7, and UBE2QL1). BCL10 mutation was identified in 6/10 CD30 + ENKTLs and 7/10 CD30 - ENKTLs. Immunohistochemical analysis revealed that the expression pattern of BCL10 in normal lymphoid tissues was similar to that of BCL2; however, its expression in ENKTL cells was significantly higher (67.92% vs. 16.98%), implying the potential application of BCL10 inhibitors for treating ENKTLs. These results provide new insights into the genetic characteristics of CD30 + and CD30 - ENKTLs, and could facilitate the clinical development of novel therapies for ENKTL.
MEMBER ACCOUNT
登录成功会直接打开下一页。